In August 2018, the results of the ARRIVE trial were published.
1 In this multicenter trial, low-risk, nulliparous women were randomized to either undergo labor induction or expectant management at 39 weeks of gestation. The study demonstrated a reduced risk of cesarean delivery (18.6% vs 22.2%; relative risk [RR], 0.84; 95% CI, 0.76-0.93) and hypertensive disorders of pregnancy (9.1% vs 14.1%; RR, 0.64; 95% CI, 0.56-0.74) in the group of women assigned to induction compared with those assigned to expectant management.
1 Furthermore, induction at 39 weeks of gestation compared with expectant management past 39 weeks was not associated with an increased risk of any neonatal complication. The results of this trial have led many clinicians to begin offering elective induction to low-risk nulliparous women at 39 weeks.